SensoLyte® 490 HIV Protease Assay Kit

Produktnummer ABIN1882480

Produktdetails

Target: HIV (Human Immunodeficiency Virus (HIV))

Reaktivität: Human Immunodeficiency Virus (HIV)

Nachweismethode: Fluorometric

Applikation: Fluorescence Resonance Energy Transfer Microscopy (FRET)

Marke: SensoLyte®

Produktmerkmale: The SensoLyte® 490 HIV Protease Assay Kit uses an optimized FRET peptide substrate for a continuous measurement of HIV protease activities. This FRET-based fluorogenic substrate is derived from a natural processing site for HIV-1 PR. Incubation of the recombinant HIV-1 PR with this substrate results in specific cleavage and a time-dependent increase in fluorescence intensity that is linearly related to the extent of substrate hydrolysis. Because of its simplicity and precision in the determination of reaction rates required for kinetic analysis, this kit offers many advantages over the commonly used HPLC or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs.

Anwendungsinformationen

Kommentare:

FRET-based Assay Kit

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Handhabung: Protect Components A and B from light.

Lagerung: -20 °C

Referenzen

Hallengärd, Haller, Petersson, Boberg, Maltais, Isaguliants, Wahren, Bråve: "Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity." in: Vaccine, Vol. 29, Issue 4, pp. 839-48, (2011) (PubMed).

Frick, Ginzburg, Lam: "A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities." in: Methods in molecular biology (Clifton, N.J.), Vol. 587, pp. 223-33, (2010) (PubMed).

Yu, Kabashima, Tang, Shibata, Kitazato, Kobayashi, Lee, Kai: "Selective and facile assay of human immunodeficiency virus protease activity by a novel fluorogenic reaction." in: Analytical biochemistry, Vol. 397, Issue 2, pp. 197-201, (2010) (PubMed).

Antigendetails

Target: HIV (Human Immunodeficiency Virus (HIV))

Abstract: HIV Produkte

Substanzklasse: Virus, Virus

Hintergrund: HIV protease (PR) is identified as an important drug-screening target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics.